Browse Medications by Drug Class: Substance P/Neurokinin-1 Receptor Antagonists

Nausea and Vomiting

NK-1 receptor antagonists are integral to preventing CINV, especially delayed-phase nausea and vomiting, which occur 24-72 hours after chemotherapy. Medications like aprepitant and fosaprepitant are used in combination with other antiemetics to provide complete protection against both acute and delayed symptoms. NK-1 receptor antagonists such as rolapitant are effective in managing PONV, reducing the risk of nausea and vomiting after surgery. They are particularly useful for patients at high risk of these complications, improving recovery and reducing hospital stays. In patients undergoing radiation therapy, NK-1 receptor antagonists help prevent RINV by targeting the neurokinin-1 receptor pathways involved in emesis. This improves patient comfort and adherence to treatment protocols.

Adults

Adults undergoing chemotherapy, radiation therapy, or surgery often benefit from NK-1 receptor antagonists to prevent nausea and vomiting. These medications are particularly valuable for individuals with a history of severe nausea or those receiving highly emetogenic therapies.

Children

NK-1 receptor antagonists are used cautiously in pediatric populations, primarily for managing CINV or PONV. Doses are adjusted based on age and weight, and close monitoring ensures safety and efficacy in younger patients.

Seniors

Seniors undergoing medical treatments that induce nausea benefit significantly from NK-1 receptor antagonists. These medications provide targeted relief without causing excessive sedation or cognitive impairment, making them suitable for older adults with complex medical needs.